Transverse myelitis
Also known as: Acute transverse myelitis, Inflammatory transverse myelopathy, Immune-mediated myelitis, Longitudinally extensive transverse myelitis
Transverse myelitis is an inflammatory myelopathy characterised by motor weakness, sensory deficits, and autonomic dysfunction, including bladder and bowel impairment. Immediate neurological evaluation is mandatory to establish aetiology and exclude other spinal emergencies. Management is cause-specific, comprising specialist medical treatment and multidisciplinary rehabilitation. Pathologies such as neuromyelitis optica spectrum disorder (NMOSD) or systemic lupus erythematosus (SLE) may be associated. TCM assessment is strictly adjunctive and symptom-focused, appropriate only post-stabilisation, as traditional diagnostic patterns cannot determine the aetiology or severity of spinal cord inflammation. The cited evidence provides no data regarding the efficacy of acupuncture or Chinese herbal medicine for transverse myelitis. Furthermore, pharmacological findings for NMOSD are not generalisable to all myelitis presentations, and rehabilitation case reports do not establish therapeutic efficacy for specific interventions.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Adhere to the pacing protocols established by the rehabilitation team, balancing physical activity with rest and monitoring for functional changes.
- •Utilise prescribed mobility aids and implement fall-prevention measures within the domestic environment; avoid unsupported balance challenges.
- •Perform daily inspections of insensate skin and adhere to prescribed pressure-relief protocols; avoid application of heat packs to areas of diminished sensation.
- •Maintain consistent nutritional intake, sleep hygiene, and the hydration and bowel/bladder management plans formulated by clinicians; fluid intake and catheterisation protocols should not be altered independently.
Cautions & Contraindications
- •Do not initiate or continue elective TCM treatment while neurological deficits are new or worsening. Urgent diagnostic assessment and medical treatment take priority; the SLE case supports prompt management rather than a trial of adjunctive therapy.[]
- •Do not replace, interrupt or reduce neurologist-prescribed relapse-prevention therapy with acupuncture or herbs. The supplied eculizumab evidence concerns AQP4-IgG-positive NMOSD specifically and does not establish equivalent benefit from TCM or apply to every cause of transverse myelitis.[]
- •In cancer-associated or atypical NMOSD presentations, herbal prescribing must be coordinated with oncology and neurology rather than delaying malignancy evaluation or disease-specific treatment. The supplied case report supports multidisciplinary management, not herbal safety or efficacy.[]
When to reassess or seek care again
Record baseline pain score, fatigue score, sleep disruption, transfers and a rehabilitation-team-approved mobility measure. Review tolerability at every visit and measurable benefit after 2–4 weeks; discontinue or revise adjunctive care if there is no meaningful improvement or adverse effects occur. Do not infer resolution of inflammation from symptom relief. New neurological loss, visual symptoms or bladder/bowel change requires immediate medical reassessment rather than waiting for the planned review.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Frontiers in oncology · 2026
- Frontiers in immunology · 2025
- Multiple sclerosis and related disorders · 2026
- Medicine · 2025
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
